Lipid lowering: An important factor in preventing adriamycin-induced heart failure

American Journal of Pathology

Volumn 150, Issue 2, 1997, Pages 727-734

  Iliskovic, Natasha ^a   Singal, Pawan K ^b,c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c ST BONIFACE GENERAL HOSPITAL RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GLUTATHIONE PEROXIDASE; MEVINOLIN; PROBUCOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOMYOPATHY; ENZYME ACTIVITY; HEART FAILURE; LIPID ANALYSIS; LIPID METABOLISM; LIPID PEROXIDATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; STATISTICAL ANALYSIS;

ANIMALS; ANTICHOLESTEREMIC AGENTS; DOXORUBICIN; GLUTATHIONE PEROXIDASE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; LIPID METABOLISM; LIPID PEROXIDES; LIPIDS; MALE; MYOCARDIUM; PROBUCOL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0031029638     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Lefrak EA, Pitha J, Rosenheim S, Gottlieb T: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973, 32:302-314
2. Yeung ST, Young C, Spink J, Galbraith A, Smit PJ: Functional myocardial impairment in children treated with anthracyclines for cancer. Lancet 1991, 337:816-818
3. Steinhertz LJ, Steinhertz PG, Tan CTC, Heller G, Murphy L: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991, 266:1672-1677
4. Singal PK, Deally CMR, Weinberg LE: Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol 1987, 19:817-828
5. Kaul N, Siveski-Iliskovic N, Hill M, Slezak J, Singal PK: Free radicals and the heart. J Pharmacol Toxicol Meth 1993, 30:55-67
6. Buja LM, Ferrans VJ, Mayer RJ, Roberts WC, Henderson ES: Cardiac ultrastructural changes induced by daunorubicin therapy. Cancer 1973, 32:771-788
7. Arena E, Biondo F, D'Alessandro N, Dusoncher L, Gebbia N, Gerbasi R: DNA, RNA, and protein synthesis in heart, liver, and brain of mice treated with daunorubicin or adriamycin. Int Res Commun Syst Med Sci 1974, 2:1053-1061
8. Bristow MR, Sageman WS, Scott RH, Billingham ME, Bowden RE, Kernoff RS, Snidow IH, Daniels JR: Acute and chronic cardiovascular effects of doxorubicin in the dog: the cardiovascular pharmacology of drug-induced histamine release. Cardiovasc Pharmacol 1980, 2:487-515
9. Tong J, Ganguly PK, Singal PK: Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. Am J Physiol 1991, 260:H909-H916
10. Gosalvez M, VanRossum GDV, Blanco MF: Inhibition of sodium-potassium activated adenosine 5-triphosphatase and non-transport by adriamycin. Cancer Res 1979, 39:257-261
11. 2+ granules in hypertrophied heart exposed to adriamycin. Can J Physiol Pharmacol 1984, 62:1239-1244
12. Singal PK, Panagia V: Direct effects of adriamycin on the rat heart sarcolemma. Res Commun Chem Pathol Pharmacol 1984, 43:67-77
13. Olson HM, Young DM, Prieur DJ, LeRoy AF, Reagan RL: Electrolyte and morphological alterations of myocardium in adriamycin-treated rabbits. Am J Pathol 1974, 77:439-454
14. Kalyanaraman B, Perez-Reyes E, Mason RP: Spin-trapping and direct electron spin resonance investigations of the redox metabolism of quinone anticancer drugs. Biochem Biophys Acta 1980, 630:119-130
15. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC: Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977, 19:165-167
16. Siveski-Iliskovic N, Kaul N, Singal PK: Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation 1994, 89:2829-2835
17. Doroshow JH: Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 1983, 43:460-472
18. Siveski-Iliskovic N, Hill M, Chow D, Singal PK: Probucol protects against adriamycin cardiomyopathy without interfering with its anti-tumor properties. Circulation 1995, 91:10-15
19. Siveski-Iliskovic N, Thomas TP, Kaul N, Slezak J, Singal PK: Doxorubicin-induced cardiomyopathy: a model of congestive heart failure. The Cardiomyopathic Heart. Edited by M Nagano, N Takeda, NS Dhalla. New York, Raven Press, 1994, 277-283
20. Paglia DE, Valentine WN: Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967, 70:158-169
21. Placer ZA, Cushman LL, Johnson BC: Estimation of product of lipid peroxidation (malondialdehyde) in biochemical systems. Anal Biochem 1966, 16:359-365
22. Aust SD: Lipid peroxidation. Handbook of Methods for Oxygen Radical Research. Edited by RA Greenwald. Boca Raton, FL, CRC Press, 1985, 203-207
23. Lowry OH, Rosenbrough NT, Farr AL, Randall AT: Protein measurements with the Folin phenol reagent. J Biol Chem 1951, 193:265-275
24. Jaenke RS, Fajardo LF: Adriamycin-induced myocardial lesions: report of a workshop. Am J Surg Pathol 1977, 1:55-60
25. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC: Early anthracycune cardiotoxicity. Am J Med 1978, 65:823-832
26. Chalcroft SCW, Gavin JB, Herdon PB: Fine structural changes in rat myocardium induced daunorubicin, Pathology 1973, 5:99-105
27. Singal PK: Adriamycin does have a potentially depressant effect on left ventricular contractility. Int J Cardiol 1985, 7:447-449
28. Deally CMR, Singal PK: Susceptibility to adriamycin-induced cardiotoxicity increases only up to a certain age. J Appl Cardiol 1990, 5:223-238
29. Weinberg LE, Singal PK: Refractory heart failure and age-related differences in adriamycin-induced myocardial changes in rats. Can J Physiol Pharmacol 1987, 65:1957-1965
30. Olson HM, Capen CC: Subacute cardiotoxicity of adriamycin in the rat. Lab Invest 1977, 37:386-394
31. Mettler FP, Young DM, Ward JM: Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res 1977, 37:2705-2713
32. Zbinden B, Bachmann E, Holdiregger C: Model systems for cardiotoxic effects of anthracyclines. Fundamentals Cancer Chemother Antibiotics Chemother 1978, 23:255-270
33. Kunitomo M, Yamaguchi Y, Matsushima K, Futagawa Y, Bandô Y: Hyperlipidemic effects of adriamycin in rats. Jpn J Pharmacol 1985, 39:323-329
34. Joles JA, van Tol A, Jansen EHJM, Doomans HA, Rabelink TJ, Grond J, van Goor H: Plasma lipoproteins and renal apolipoproteins in rats with chronic adriamycin nephrosis. Nephrol Dial Transplant 1993, 8:831-838
35. Washio M, Nanishi F, Okuda S, Onoyama K, Fujishima M: α-Tocopherol improves focal glomerulosclerosis in rats with adriamycin-induced progressive renal failure. Nephron 1994, 68:347-352
36. Modi KS, Morrissey J, Shah SV, Schreiner GF, Klahr S: Effects of probucol on renal function in rats with bilateral ureteral obstruction. Kidney Int 1990, 38:843-850
37. Willebrands AF, Ter Welle HF, Tasseron SJA: The effect of a high molar FFA/albumin ratio in the perfusion medium on rhythm and contractility of the isolated rat heart. J Mol Cell Cardiol 1973, 5:259-273
38. Senekowitsch R, Lohninger A, Kriegel H, Staniek H, Kreiglsteiner H-P, Kaiser E: Protective effects of carnitine on adriamycin toxicity to heart. Carnitine: Its Role in Lung and Heart Disorders. Edited by E Kaiser, A Lohninger. Graz, Austria, Proc Satell Symp ZAK, 1985, pp 126-137
39. Bremer J: Carnitine metabolism and function. Physiol Rev 1983, 63:1420-1480
40. Skutelsky E, Hartzan S, Socher R, Gafter U: Modifications in glomerular polyanion distribution in adriamycin nephrosis. J Am Soc Nephrol 1995, 5:1799-1805
41. Doroshow JH, Locker GY, Myers CE: Enzymatic defenses of the mouse heart against reactive oxygen .metabolites, J Clin Invest 1980, 65:128-135 /